H.C. Wainwright analyst Ed Arce maintained a Buy rating on Inventiva (IVA) today and set a price target of $38.00. The company’s shares closed last Friday at $15.00.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 16.9% and a 43.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Inventiva has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.06 and a one-year low of $9.01. Currently, Inventiva has an average volume of 45.86K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company’s operations are located in France.
